Sutro Biopharma appoints Gregory K. Chow as CFO effective June 2, 2025

SUTRO BIOPHARMA, INC.

Gregory K. Chow appointed CFO, principal financial and accounting officer, effective June 2, 2025.
Base salary $475,000; target annual bonus 40% of base salary.
Receives option for 275,000 shares (4-year vest) and 100,000 RSUs (4-year vest).
Prior roles: CFO of NodThera (Aug 2024-Mar 2025), Freenome (Jan-Aug 2024), Frontier Medicines (Mar 2021-Dec 2024).
Severance on non-cause termination: 15 months salary + pro-rata bonus + COBRA; full acceleration upon change in control within 18 months.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gregory K. Chow

Chief Financial Officer

STRO · SUTRO BIOPHARMA, INC.

Effective: 2025-06-02
Filed: June 2, 2025, 7:59 PM ET

On June 2, 2025 Sutro Biopharma, Inc. (the “Company”) announced the appointment of Gregory K. Chow as its Chief Financial Officer, principal financial officer and principal accounting officer, effective as of June 2, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Gregory K. Chow was appointed as Chief Financial Officer at SUTRO BIOPHARMA, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 2, 2025 Sutro Biopharma, Inc. (the “Company”) announced the appointment of Gregory K. Chow as its Chief Financial Officer, principal financial officer and principal accounting officer, effective as of June 2, 2025.

View on SEC.gov

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-133268

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.